Heart and lung diseases are the leading causes of death worldwide with unmet treatment challenges that can only be tackled by deciphering the molecular biology underlying individual cellular phenotypes and intercellular as well as inter-organ cooperativity. Similarly, understanding of failed regulation in disease and its exploitation for novel therapies is lacking. These challenges in molecular medicine are addressed by the Cardiopulmonary Institute (CPI) a consortium of basic scientists, translationally-oriented researchers and clinicians at the universities of Frankfurt (GU) and Giessen (JLU) and the Max Planck Institute for Heart and Lung Research (MPI-HLR). This consortium is funded by the Excellence Strategy program of the German Research Foundation and is now seeking additional expertise in emerging fields
